Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Lambert

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Clinical and Translational Science|March 9, 2018
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein InhibitorHans Ericsson, Karin Nelander, Maria Lagerstrom-Fermer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2010
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT studyHans-Jürgen Stellbrink, Chloe Orkin, Jose Ramon Arribas, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2015
The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1Silas Bond, Alistair G Draffan, Jennifer E Fenner, et al.
Antiviral Therapy|July 4, 2014
Atazanavir exposure is effective during pregnancy regardless of tenofovir useAngela Colbers, David Hawkins, Carmen Hidalgo-Tenorio, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2015
1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidateSilas Bond, Alistair G Draffan, Jennifer E Fenner, et al.
The Journal of Infectious Diseases|November 17, 2005
Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected womenDaniel C Johnson, Elizabeth J McFarland, Petronella Muresan, et al.
Science (New York, N.Y.)|January 1, 2021
Mapping the global threat of land subsidenceGerardo Herrera-García, Pablo Ezquerro, Roberto Tomás, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Clinical and Translational Science|March 9, 2018
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein InhibitorHans Ericsson, Karin Nelander, Maria Lagerstrom-Fermer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2010
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT studyHans-Jürgen Stellbrink, Chloe Orkin, Jose Ramon Arribas, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2015
The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1Silas Bond, Alistair G Draffan, Jennifer E Fenner, et al.
Antiviral Therapy|July 4, 2014
Atazanavir exposure is effective during pregnancy regardless of tenofovir useAngela Colbers, David Hawkins, Carmen Hidalgo-Tenorio, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2015
1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidateSilas Bond, Alistair G Draffan, Jennifer E Fenner, et al.
The Journal of Infectious Diseases|November 17, 2005
Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected womenDaniel C Johnson, Elizabeth J McFarland, Petronella Muresan, et al.
Science (New York, N.Y.)|January 1, 2021
Mapping the global threat of land subsidenceGerardo Herrera-García, Pablo Ezquerro, Roberto Tomás, et al.
Pageof 5